Janssen Pharmaceutica Nv

Alejandro Santillán, Jr

Cheryl A Grice

Laurent Gomez

John J M Wiener

Liu Y Tang

Aaron M Kearney

Adrienne M Landry-Bayle

Hariharan Venkatesan

Genesis M Bacani

Alice Lee-Dutra

Ronald L Wolin

Michael D Hack

Christa C Chrovian

Wendy Eccles

Brett D Allison

Virginia M Tanis

Kimberly Schwarz

Timothy W Lovenberg

Charles Q Huang

Scott D Bembenek

Karen Joy Shaw

Kathleen C Sappey

Kia Sepassi

Taraneh Mirzadegan

Brian J Morrow

S Timothy Motley

Eugene Y Cheung

Alvah T Wickboldt

James Patrick Edwards

Neelakandha S Mani

Xiaohu Deng

Kelly J McClure

Anne Fourie

Susanne Lochner

Jimmy T Liang

Diego Broggini

Hartmut B Zinser

Tristin K Barclay

Anne M Fourie

Anne M Fourine

Compounds with two fused bicyclic heteroaryl moieties and their pharmaceutical compositions, and methods of using them as leukotriene Ahydrolase (LTAH) modulators and for the treatment of diseases, disorders and conditions mediated by LTAH.

[object Object]

Aryl-substituted bridged or fused diamine compounds, pharmaceutical compositions containing them, and methods of using the compounds and the pharmaceutical compositions for leukotriene Ahydrolase (LTAH or LTA4H) modulation and for the treatment of disease states, disorders, and conditions mediated by LTAH activity, such as allergy, asthma, autoimmune diseases, pruritis, inflammatory bowel disease, ulcerative colitis, and cardiovascular disease, including atherosclerosis and prevention of myocardial infarction.

Thiazolopyridin-2-yloxy-phenyl and thiazolopyrazin-2-yloxy-phenyl amine compounds are described, which are useful as LTA4 hydrolase (LTA4H) modulators. Such compounds may be used in pharmaceutical compositions and methods for modulation of LTA4H and for the treatment of disease states, disorders, and conditions mediated by LTA4 hydrolase activity.

Thyazolopyridin-2-yloxy-phenyl and thiazolopyrazin-2-yloxy-phenyl amines as modulators of leukotriene A4 hydrolase

Antibacterial compounds, compositions containing them, and methods of use for the inhibition of bacterial activity and the treatment, prevention or inhibition of bacterial infection.

Bicyclic pyrazole compounds as antibacterial agents

Thiazolopyridin-2-yloxy-phenyl and thiazolopyrazin-2-yloxy-phenyl amines as modulators of leukotriene A4 hydrolase

The invention provides novel GlyT2 inhibiting compounds useful in modulating, treating, or preventing: anxiolytic disorders; a condition requiring treatment of injured mammalian nerve tissue; a condition amenable to treatment through administration of a neurotrophic factor; a neurological disorder; or obesity; an obesity-related disorder.

Aryl piperidine amides

Certain &#x3b1;-, &#x3b2;-, and &#x3b3;-amino acid derivatives are disclosed as selective GlyT2 inhibitors for the treatment of central nervous system (CNS) conditions such as muscle spasticity, tinnitus, epilepsy and neuropathic pain.

GlyT2 modulators

Growing community of inventors

San Diego, CA, United States of America

Alejandro Santillán, Jr